- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Jenburkt Pharmaceuticals Limited has submitted its Annual Secretarial Compliance Report by Nilesh Shah & Associates for the financial year ended March 31, 2025. The report confirms general compliance with applicable SEBI regulations and timely filings, except for delayed revised filings of quarterly shareholding patterns for June 2024 and June 2023 quarters due to system issues with BSE treating revisions as fresh filings, resulting in repeated submissions. The company has taken corrective actions to address these delays. A promoter sold shares during the trading window closure in July 2023, violating insider trading norms; a fine of ₹10,000 and a warning letter were issued. No other significant non-compliances were observed.